Registration Strip Icon for pro Trade like a pro: Leverage real-time discussions and market-moving ideas to outperform.

SYRE

Spyre Therapeutics (SYRE)

Spyre Therapeutics Inc
Date:
Sort by:
 Showing the most relevant articles for your search:NASDAQ:SYRE
DateTimeSourceHeadlineSymbolCompany
12/18/20247:00AMPR Newswire (US)Spyre Therapeutics Added to the Nasdaq Biotechnology IndexNASDAQ:SYRESpyre Therapeutics Inc
12/02/20244:03PMPR Newswire (US)Spyre Therapeutics Announces Grants of Inducement AwardsNASDAQ:SYRESpyre Therapeutics Inc
12/02/20247:00AMPR Newswire (US)Spyre Therapeutics Announces First Participants Dosed in Phase 1 Trials of Novel Half-life Extended Anti-TL1A AntibodiesNASDAQ:SYRESpyre Therapeutics Inc
11/25/20244:11PMPR Newswire (US)Spyre Therapeutics to Participate in the 7th Annual Evercore ISI HealthCONx ConferenceNASDAQ:SYRESpyre Therapeutics Inc
11/19/20244:15PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:SYRESpyre Therapeutics Inc
11/19/20243:38PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:SYRESpyre Therapeutics Inc
11/18/20248:18PMPR Newswire (US)Spyre Therapeutics Announces Pricing of $200 Million Public Offering of Common StockNASDAQ:SYRESpyre Therapeutics Inc
11/18/20244:10PMEdgar (US Regulatory)Form 424B5 - Prospectus [Rule 424(b)(5)]NASDAQ:SYRESpyre Therapeutics Inc
11/18/20243:14PMPR Newswire (US)Spyre Therapeutics Announces Proposed Public Offering of its Common Stock and Pre-Funded WarrantsNASDAQ:SYRESpyre Therapeutics Inc
11/18/20243:09PMEdgar (US Regulatory)Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]NASDAQ:SYRESpyre Therapeutics Inc
11/18/20243:06PMEdgar (US Regulatory)Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]NASDAQ:SYRESpyre Therapeutics Inc
11/18/20243:05PMEdgar (US Regulatory)Form 10-Q/A - Quarterly report [Sections 13 or 15(d)]: [Amend]NASDAQ:SYRESpyre Therapeutics Inc
11/18/20243:03PMEdgar (US Regulatory)Form 10-K/A - Annual report [Section 13 and 15(d), not S-K Item 405]: [Amend]NASDAQ:SYRESpyre Therapeutics Inc
11/18/20243:01PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:SYRESpyre Therapeutics Inc
11/14/20244:50PMEdgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:SYRESpyre Therapeutics Inc
11/14/20243:05PMEdgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:SYRESpyre Therapeutics Inc
11/14/20248:44AMEdgar (US Regulatory)Form SC 13G/A - Statement of Beneficial Ownership by Certain Investors: [Amend]NASDAQ:SYRESpyre Therapeutics Inc
11/12/20246:30AMPR Newswire (US)Spyre Therapeutics Announces Positive Interim Results from Phase 1 Healthy Volunteer Trial for SPY001, Its Novel Half-Life Extended anti-α4β7 Antibody for the Treatment of Inflammatory Bowel Disease, with a Half-Life of >90 Days Supporting the PotentialNASDAQ:SYRESpyre Therapeutics Inc
11/11/20243:05PMPR Newswire (US)Spyre Therapeutics to Host Conference Call and Webcast to Report Interim Results from Phase 1 Healthy Volunteer Trial for SPY001, its Novel Half-Life Extended Anti-α4β7 Antibody for the Treatment for Inflammatory Bowel Disease on November 12, 2024NASDAQ:SYRESpyre Therapeutics Inc
11/08/20243:53PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SYRESpyre Therapeutics Inc
11/07/20243:14PMEdgar (US Regulatory)Form S-8 - Securities to be offered to employees in employee benefit plansNASDAQ:SYRESpyre Therapeutics Inc
11/07/20243:06PMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:SYRESpyre Therapeutics Inc
11/07/20243:05PMPR Newswire (US)Spyre Therapeutics Reports Third Quarter 2024 Financial Results and Provides Corporate UpdateNASDAQ:SYRESpyre Therapeutics Inc
11/07/20243:01PMEdgar (US Regulatory)Form 10-Q - Quarterly report [Sections 13 or 15(d)]NASDAQ:SYRESpyre Therapeutics Inc
11/01/20243:44PMPR Newswire (US)Spyre Therapeutics Announces Grants of Inducement AwardsNASDAQ:SYRESpyre Therapeutics Inc
10/30/20243:05PMPR Newswire (US)Spyre Therapeutics to Participate in Upcoming November Investor ConferencesNASDAQ:SYRESpyre Therapeutics Inc
10/28/20243:41PMEdgar (US Regulatory)Form 4 - Statement of changes in beneficial ownership of securitiesNASDAQ:SYRESpyre Therapeutics Inc
10/25/20243:28PMEdgar (US Regulatory)Form 144 - Report of proposed sale of securitiesNASDAQ:SYRESpyre Therapeutics Inc
10/23/20241:10PMEdgar (US Regulatory)Form SC 13G - Statement of Beneficial Ownership by Certain InvestorsNASDAQ:SYRESpyre Therapeutics Inc
10/15/20245:10AMEdgar (US Regulatory)Form 8-K - Current reportNASDAQ:SYRESpyre Therapeutics Inc
 Showing the most relevant articles for your search:NASDAQ:SYRE